Akèy › Obèsite › Nevada › Las Vegas
Etid klinik pou Obèsite nan Las Vegas, NV
27 etid pou Obèsite ap chèche patisipan nan sit nan ak bò kote Las Vegas (nan yon distans apeprè 30 mil). Louvri yon etid pou wè ki moun ki ka patisipe ak kijan pou kontakte ekip etid la.
Tèks ofisyèl etid la (Anglè)
Ap chèche patisipan pou yon etid? Mete l anwo paj sa a — $99 pou 30 jou →
Safety and Efficacy of ABBV-295 in Adults With Obesity or Overweight With Weight-Related Comorbidities
Ap rekriteFaz 2
- Vector Clinical Trials /ID# 282265, Las Vegas
A Study of Clazakizumab (LY5724886) in Adults With Elevated hsCRP and at Increased Risk for Cardiovascular Event
Ap rekriteFaz 2
- Excel Clinical Research, LLC, Las Vegas
- Palm Research Center Tenaya, Las Vegas
AMAZE 9: A Research Study Investigating How Well Zenagamtide Tablets Help People With Excess Body Weight Lose Weight
Ap rekriteFaz 3
- Palm Research Center Inc., Las Vegas
A Study to Evaluate Effect of AZD6234 as an Adjunct to Incretin-based Therapies in Adult Participants With Obesity or Overweight With Weight-related Comorbidity With or Without Type 2 Diabetes Mellitus
Ap rekriteFaz 3
- Research Site, Las Vegas
A Study of Eloralintide (LY3841136) in Participants With Obstructive Sleep Apnea and Obesity or Overweight
Ap rekriteFaz 3
- Palm Research Center Tenaya, Las Vegas
Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity
Ap rekriteFaz 3
- Excel Clinical Research, Las Vegas
- Vector Clinical Trials, Las Vegas
A Study of Eloralintide (LY3841136) in Participants With Obesity, or Overweight Without Type 2 Diabetes
Ap rekriteFaz 3
- AMR Clinical, Las Vegas
A Study to Investigate Weight Management With Macupatide and Eloralintide, Alone or in Combination, in Adult Participants With Obesity or Overweight
Ap rekriteFaz 2
- Las Vegas Medical Research, Las Vegas
A Study of Once-daily Oral ASC30 to Evaluate the Efficacy and Safety in Adult Participants With Obesity or Overweight With Weight-Related Comorbidities
Ap rekriteFaz 3
- AURORA-1 Clinical Site, Las Vegas
A Study of Once-daily Oral ASC30 to Evaluate the Efficacy and Safety in Adult Participants With Obesity or Overweight With Type 2 Diabetes
Ap rekriteFaz 3
- AURORA-2 Clinical Site, Las Vegas
A Study of Aleniglipron in Adults With Obesity or Overweight and Type 2 Diabetes Mellitus (ACCOMPLISH-2)
Ap rekriteFaz 3Volontè an sante akeyi
- ACCOMPLISH-2 Research Site, Las Vegas
Research Study on How Well Oral Semaglutide Works for Weight Loss in Adults With Excess Body Weight
Ap rekriteFaz 3
- Jubilee Clinical Research, Inc., Las Vegas
A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or Overweight
Ap rekriteFaz 2
- Las Vegas Medical Research, Las Vegas
A Study of Macupatide (LY3532226) and Eloralintide (LY3841136), Alone or in Combination, in Adults With Obesity or Overweight and With Type 2 Diabetes
Ap rekriteFaz 2
- Vector Clinical Trials, Las Vegas
Efficacy and Safety of Ribupatide Administered Once Weekly in Participants Living With Obesity or Overweight and Diabetes
Ap rekriteFaz 3
- Kailera Clinical Site, Las Vegas
Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-1-EXTENSION)
Ap rekriteFaz 3
- Palm Research Center Inc, Las Vegas
- Vector Clinical Trials, Las Vegas
Efficacy and Safety of Ribupatide in Participants Living With Obesity or Overweight With Weight-Related Comorbidities Who Do Not Have Diabetes
Ap rekriteFaz 3
- Kailera Clinical Site, Las Vegas
Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-2-EXTENSION)
Ap rekriteFaz 3
- Palm Research Center Inc, Las Vegas
Efficacy and Safety of Ribupatide Administered Once Weekly Compared With Semaglutide and Placebo in Participants Living With Obesity Who Do Not Have Diabetes
Ap rekriteFaz 3
- Kailera Clinical Site, Las Vegas
Efficacy, Safety and Tolerability of Switching From Glucagon-like Peptide-1 Receptor Agonists (GLP-1RA) to Maridebart Cafraglutide in Adults With Obesity or Overweight (MARITIME-SWITCH)
Ap rekriteFaz 3
- Excel Clinical Research, Las Vegas
Assess the Effects of Replacing Foods High in Refined Carbohydrates With Avocado on Biomarkers of Inflammation.
Ap rekriteVolontè an sante akeyi
- University of Nevada, Las Vegas, Las Vegas
A Study to Evaluate Effect of AZD6234 in Adult Participants With Obesity or Overweight With Weight-related Comorbidity Without Type 2 Diabetes Mellitus
Ap rekriteFaz 3
- Research Site, Las Vegas
A Research Study to Look at How Well NNC0487-0111 Works Compared to Placebo in People With Heart Failure and Obesity
Ap rekriteFaz 3
- UMC of Southern Nevada, Las Vegas
- Palm Research Center Inc-Vegas, Las Vegas
Efficacy and Safety of Aleniglipron in Participants With Obesity or Overweight With a Weight-Related Comorbidity (ACCOMPLISH-1)
Ap rekriteFaz 3
- ACCOMPLISH-1 Research Site, Las Vegas
A Study to See How Safe and Effective Alirocumab is When Given Weekly to Adult Participants Who Have Hypercholesterolemia
Ap rekriteFaz 2
- Palm Research Center, Mountainview Medical Center, Las Vegas
A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Knee Osteoarthritis Lose Weight and Reduce Pain
Ap rekriteFaz 3
- Jubilee Clinical Research, Inc., Las Vegas
A Study to Evaluate the Safety and Tolerability of Different Doses of CX11 Tablets
Ap rekriteFaz 1
- Corxel Investigational site, Las Vegas
Etid Obèsite nan lòt vil
- Houston, TX43 etid
- Chicago, IL41 etid
- New York City, NY40 etid
- San Antonio, TX40 etid
- Washington, DC33 etid
- Orlando, FL31 etid
- Dallas, TX30 etid
- Boston, MA28 etid
- Miami, FL27 etid
- Baltimore, MD25 etid
- Jacksonville, FL25 etid
- St. Louis, MO25 etid
Lòt etid nan Las Vegas
- Sipwa23 etid
- Dyabèt Tip 218 etid
- Kansè Poumon ki pa ti selil13 etid
- Twoub depresif majè13 etid
- Kansè nan tete10 etid
- Maladi Alzheimer8 etid
- Kansè pwostat8 etid
- Leksemi mieloïd egi8 etid
- Kansè (tout kalite)8 etid
- Maladi fwa steatotik7 etid
- Kansè Endomèt7 etid
- Depresyon7 etid
Sous ClinicalTrials.gov, done yo ranmase Oct 5, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.